News

The pivotal study, which will be carried out under an FDA fast track designation, will include patients with the most common form of cutaneous T-cell lymphoma (CTCL), mycosis

Under the agreement, which was unanimously approved by Orphan Medical’s board of directors, Orphan Medical common stockholders will receive $10.75 per share in cash upon the close of

Gefitinib (marketed as Iressa by AstraZeneca) has been recently approved for clinical treatment of patients with advanced non-small cell lung cancer (NSCLC) and is an inhibitor of epidermal

Pfizer’s first-quarter net income was $301 million, or 4 cents a share, compared to $2.33 billion, or 30 cents a share, last year. Revenues for the first quarter

The organizations’ first common award program is seeking applications focused on technologies that can achieve selective targeting and/or delivery of therapeutic agents to specific regions or cells in

The FDA has now approved an investigational new drug (IND) application for a phase II study of AS1404 in hormone-refractory prostate cancer. This study, in which AS1404 will

The preclinical data were presented at the American Association for Cancer Research (AACR) annual meeting in Anaheim, California. ImmunoGen developed this CD33-targeting compound for the treatment of acute

The analysis, from researchers at North Shore University Hospital in New York and the University of Michigan Cardiovascular Center, estimates that patients treated with the intravenous drug nesiritide

The clinical trial, which was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, was designed to compare AstraZeneca’s Iressa (gefitinib) to placebo